Compare BOW & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOW | SLS |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 734.3M | 706.7M |
| IPO Year | 2024 | 2007 |
| Metric | BOW | SLS |
|---|---|---|
| Price | $24.13 | $4.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $32.29 | $10.00 |
| AVG Volume (30 Days) | 159.7K | ★ 5.9M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.26 | ★ 50.00 |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $551,589,000.00 | N/A |
| Revenue This Year | $21.42 | N/A |
| Revenue Next Year | $19.41 | $67.40 |
| P/E Ratio | $15.38 | ★ N/A |
| Revenue Growth | ★ 29.58 | N/A |
| 52 Week Low | $21.21 | $1.26 |
| 52 Week High | $41.98 | $6.14 |
| Indicator | BOW | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 52.42 |
| Support Level | $23.72 | $4.70 |
| Resistance Level | $26.17 | $5.01 |
| Average True Range (ATR) | 0.80 | 0.33 |
| MACD | 0.32 | 0.02 |
| Stochastic Oscillator | 84.62 | 61.76 |
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division, which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury, or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity, and hospitality segments, and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.